ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.

[1]  J. Moon,et al.  Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. , 2019, JACC. Cardiovascular imaging.

[2]  D. Phelan,et al.  Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. , 2018, Journal of the American College of Cardiology.

[3]  J. Berk,et al.  Once AL amyloidosis: not always AL amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[4]  S. Rajkumar,et al.  How I manage monoclonal gammopathy of undetermined significance. , 2018, Blood.

[5]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[6]  M. Maurer,et al.  Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[7]  P. Schoenhagen,et al.  ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease , 2017, Journal of Nuclear Cardiology.

[8]  R. Falk,et al.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.

[9]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[10]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[11]  Harold Litt,et al.  2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology , 2016, Journal of the American College of Cardiology.

[12]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[13]  T. Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[14]  L. Shaw,et al.  ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Societ , 2014, Journal of the American College of Cardiology.

[15]  Richard D. White,et al.  2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. , 2013, Journal of the American College of Cardiology.

[16]  M. Dimopoulos,et al.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.

[17]  Manesh R. Patel,et al.  Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation appropriate use criteria task force. , 2013, Journal of the American College of Cardiology.

[18]  A. Flett,et al.  Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis: An Equilibrium Contrast Cardiovascular Magnetic Resonance Study , 2013, Circulation. Cardiovascular imaging.

[19]  John Eng,et al.  Normal Left Ventricular Myocardial Thickness for Middle-Aged and Older Subjects With Steady-State Free Precession Cardiac Magnetic Resonance: The Multi-Ethnic Study of Atherosclerosis , 2012, Circulation. Cardiovascular imaging.

[20]  Warren J Manning,et al.  ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, , 2011, Journal of the American College of Cardiology.

[21]  Manesh R. Patel,et al.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. , 2010, Circulation.

[22]  M. Keith,et al.  American Academy of Orthopaedic Surgeons Clinical Practice Guideline on diagnosis of carpal tunnel syndrome. , 2009, The Journal of bone and joint surgery. American volume.

[23]  Michael J Pentecost,et al.  American College of Radiology white paper on radiation dose in medicine. , 2007, Journal of the American College of Radiology : JACR.

[24]  G. Merlini,et al.  Dangerous small B-cell clones. , 2006, Blood.

[25]  R. Hendel,et al.  ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. , 2005, Journal of the American College of Cardiology.

[26]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[27]  A. Balduini,et al.  Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.

[28]  L Goldman,et al.  Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. , 1999, JAMA.

[29]  R H Brook,et al.  A Method for the Detailed Assessment of the Appropriateness of Medical Technologies , 1986, International Journal of Technology Assessment in Health Care.

[30]  Warren J Manning,et al.  ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, Americ , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[32]  J. Berk,et al.  Contemporary Reviews in Cardiovascular Medicine Transthyretin (TTR) Cardiac Amyloidosis , 2012 .

[33]  A. P. Meijler,et al.  Setting standards for effectiveness: a comparison of expert panels and decision analysis. , 1997, International journal for quality in health care : journal of the International Society for Quality in Health Care.